This line of inquiry was common to us when one researcher from our network sent us a question three years ago. "I read about BPC-157 in 40 forum writings, but I'm still clueless about the actual research findings as regards what dose was used in the rats, and whether it's even legal to buy it or not." This inquiry, however, is the reason why this article was written. BPC-157 has a unique position: tons of strong preclinical healing data in peptide studies, zero human clinical trials, a complex FDA history, and a market replete with vials of different purity levels. We'll take it step by step, source by source.
If you came here for a purchase, here is where our audience gets to order BPC-157 10 mg vial at US Peptide Labs – 99.4% pure in HPLC, along with a lot-specific Certificate of Analysis from AxisPharm. The balance of this article is the education layer that supports that buying decision.
Research has made it possible for scientists to create a synthetic peptide, known as BPC-157, which consists of a series of 15 amino acids imported from the father protein found in gastric fluid. The term "synthetic" indicates that this peptide does not naturally occur in the body, meaning that scientists had to extract the leading protein from gastric tissue and create a stable version. The name BPC-157 stands for Body Protection Compound-157, and it reflects the peptide’s research background.
BPC-157 illustrates two mechanisms of action. First, in terms of the FAK-paxillin pathway, in vitro and tendon explant studies demonstrates that BPC-157 activates the protein FAK and paxillin, which regulate fibroblast attachment to and motility through the extracellular matrix. It is known that fibroblast movement is the bottleneck in the process of connective tissue healing; thus, entry to the system leads to faster healing in experimental studies in animals.
The second pathway entails the use of the system involving nitric oxide (NO). BPC-157 works on endothelial nitric oxide synthase which stimulates the process of angiogenesis – the creation of new blood vessels. New blood vessels are immensely important because they supply oxygen as well as growth factors to the site of injury. This is why the effects of angiogenesis have also generated controversies when talking about cancer risk (more on this below).
Both pathways have BPC-157 acting through the mechanisms of interaction with growth factor receptors, such as the vascular endothelial growth factor receptor 2 (VEGFR2) and epidermal growth factor receptor (EGFR), although the binding mechanism remains not clearly defined. The mechanism itself seems plausible and internally consistent, however made mostly from rodents’ tissue and cell cultures as well.
The half-life of BPC-157 plasma is relatively short, usually in the range of minutes to few hours, depending on administration route and the model. This is a key pharmacokinetic factor for research protocols choosing daily dosing regime over every other day or weekly dosing. It is quickly eliminated from the body, which means it is unlikely to accumulate in the body to a detectable level for standard urine drug screening (but it is prohibited in sport for other reasons).
Subcutaneous injection has a local depot effect in the proximity of injection, which may prolong local exposure for more than what plasma half-life would indicate. The local concentration hypothesis is the basis of why the injury area should be injected instead of a distant area.
The key number that needs to be remembered before considering any statement about beneficial effects is only three pilot human studies of BPC-157 exist as of the most recent systematic review, and that statistic does not come from any huge, random, double-blind trial. Everything else available in the benefit literature is either based on rodent tests or in vitro tests. Preclinical data is still useful, however - in fact, it is remarkably consistent across various species and laboratories, but that means that every claim that follows has that important asterisk.
This point has achieved significant documentation in the literature devoted to BPC-157. The effect of BPC-157 has been thoroughly investigated, leading to faster tendon healing through better fibroblast movement and tendon processing in vitro. In various rodent animal models involving Achilles tendon transection, rotator cuff injury, and medial collateral ligament damage, the results were faster both histologically and functionally than in controls.Overall, BPC-157 is one of the peptides that have been studied the most in preclinical conditions.
Studies have been conducted examining plantar fasciitis and arthritis, but this science is less developed. There have been studies that have looked at arthritis models in rats and while these studies showed reduced markers for synovial inflammation, the dosing protocols employed in these studies do not correlate well with anything tested in humans. Details on the type of study are available in joint healing peptide research guide on this web page.
The foundational research context of BPC-157 was gastric cytoprotection before its first human trials in Phase II for inflammatory bowel disease as PL 14736, a topical rectal formulation. This is BPC-157’s nearest approximation to clinical data involving humans, and it involves a specific, topical use as opposed to a systemic application.
In animal studies concerning NSAID-caused stomach damage, ethanol-induced ulcers and surgically induced colitis, BPC-157 consistently beats the control groups in terms of mucosal healing targets. The proposed NO-system connection here is possible since nitric oxide is important for mucosal blood flow and barrier function. Our paper provides more details about the comparisons between the studies.
Studies on rodents that examine the injury of the knee cartilage and spinal discs demonstrate that BPC-157 leads to the reduction of inflammatory markers and the improvement in the tissue architecture scores in the histological studies. In terms of knee pain, the hypothesis for local injection of BPC-157 around the injured joint is valid as evidenced by the angiogenesis and fibroblast studies, both of which are significant to the recovery of the cartilage and synovial membrane.
Herniated disc research is the least impressive of the three fields. There is a limited number of rodent studies revealing a decrease in markers for degeneration of the nucleus pulposus, but the conditions of the studies are hugely artificial. Anyone referring to strong evidence from studies in humans of BPC-157 in disc pathology is taking their statements far beyond that which the literature supports.
There are three subjects on which BPC-157 is most overhyped in messages, namely; body composition, muscle fiber structure, and hair growth. Some rodent studies showed changes in body composition and muscle fiber structure at high doses, but those findings are very inconsistent and the effect sizes are small compared to the ones from actual substances that were investigated in regards to those effects. In hair growth, there is only the very limited research done on BPC-157, and because of that basically every claim about BPC-157 for that purpose is pure speculation and based on the assumption that the angiogenesis process works the same way in hair follicle vascularization. In this article we cover these topics merely because researchers are interested, not because the evidence is enough to rely on.
Published literature does not report a significant sex-dependent reaction to BPC-157's therapeutic efficacy on rodents. Studies generally use female or male animals without any discrepancy in the results. This inquiry arises mostly due to the fears regarding the effects of hormones because, as far as we know at the moment, BPC-157 does not have androgenic or estrogenic properties and thus must affect musculoskeletal and gut outcomes the same way regardless of sex. Lack of studies on humans means that such a conclusion cannot be stated even more firmly.
In rodent tendon transection studies, there are substantial histological variances at the one- to two-week mark with daily administration. Functional recovery outcomes - load to failure, range of motion - show greater variances at week four. From the gut models perspective, mucosal changes occur within days. The above timetables are animal schedules in controlled settings rather than human before-after predictions. Research parameters commonly last from four to eight weeks, which correlates with the rodent trecovery times although human data is lacking to ground the timing.
The numbers given in this part are taken from published studies involving rodents or from the doses used in phase II IBD studies. Please note that this is a research guide and not one for personal use. The full BPC-157 compound profile explains the references used for each phrase in our library of peptides.
| Body Weight (lbs) | Body Weight (kg) | Daily Dose at 10 mcg/kg | Daily Dose at 15 mcg/kg |
|---|---|---|---|
| 110 lbs | 50 kg. | 500 mcg. | 750 mcg. |
| 132 lbs | 60 kg. | 600 mcg. | 900 mcg. |
| 154 lbs | 70 kg. | 700 mcg. | 1050 mcg. |
| 176 lbs | 80 kg. | 800 mcg. | 1200 mcg. |
| 198 lbs | 90 kg. | 900 mcg. | 1350 mcg. |
| 220 lbs | 100 kg. | 1000 mcg. | 1500 mcg. |
The benchmark of 10 mcg/kg has gained prominence in rat studies. The figure in the second line of 15 mcg/kg marks the maximum measurement considered for some models involving effective musculoskeletal injury. Please do not interpret these figures as clinical guidelines to follow in humans.
In the table below, one assumes a reconstitution of 2 ml bacteriostatic water for the 5 mg vial and 2 ml for the 10 mg vial, yielding 2500 mcg/ml and 5000 mcg/ml respectively. To make adjustments for different reconstitution volumes, follow peptide dosage calculator.
| Target Dose | 5 mg Vial / 2 ml (2500 mcg/ml) - Volume | 5 mg Vial - IU on Syringe | 10 mg Vial / 2 ml (5000 mcg/ml) - Volume | 10 mg Vial - IU on Syringe |
|---|---|---|---|---|
| 250 mcg | 0.10 ml. | 10 IU. | 0.05 ml. | 5 IU. |
| 500 mcg | 0.20 ml. | 20 IU. | 0.10 ml. | 10 IU. |
| 750 mcg | 0.30 ml. | 30 IU. | 0.15 ml. | 15 IU. |
| 1000 mcg | 0.40 ml. | 40 IU. | 0.20 ml. | 20 IU. |
| 1500 mcg | 0.60 ml. | 60 IU. | 0.30 ml. | 30 IU. |
Rodent studies have been conducted for durations ranging from 7 days (in case of acute injury model) to 12 weeks (where chronic degeneration models) have been utilized but the time duration most commonly used has been 4-8 weeks of continuous application. The cited document mentions the specific parameters followed by leading studies in this regard. The period of 4 weeks has been specified as this is suitable for acute tendon injuries while elsewhere the span of 6-8 weeks of treatment has been recommended in regards to chronic musculoskeletal injuries. So far, nothing has been published on the long-term treatment following 12 weeks of continuous administration in any model.
The existing publications on studies conducted on rats with BPC-157 do not use the time of day as the administration schedule, but instead choose to give for example BPC-157 two times a day consistently at fixed intervals. As for the time of administration of BPC-157, there are no studies specifically on this topic available so far. The use of two times a day administration may indicate that BPC-157 has a short plasma half life and not that the possible using of BPC-157 three times a day at given time is effective.
BPC-157 powder in lyophilized form has to be combined with bacteriostatic water, but not sterile water or saline, for reconstitution, because the benzyl alcohol content of bacteriostatic water stops micro-organism growth in the time of storage after opening it. The optimal volume of bacteriostatic water to use in research is from 1 to 3 ml per vial, depending on the desired concentration. For example, for the vial of 10 mg one has to use 2 ml of bacteriostatic water to get a concentration of 5000 mcg/ml (5 mcg/ul), hence, all injections fall in the range of volumes manageable for syringes. Water has to be added into the vial gently while swaying it, without shaking. When reconstitution has been completed, the reconstituted product has to be placed in a refrigerator at the temperature ranging from 2 to 8 degrees Celsius without being used for 4 weeks. Lyophilized powder must be stored in refrigerated or frozen conditions away from the light until the time of reconstitution.
In case of customized reconstitution quantities and dose-to-volume conversions, Get US Peptides dosage calculator should be used - it works with any vial size and target concentration without needing manual calculation.
Both methods are used in research, but they have different uses and bioavailability profiles. Whether one or the other should be used might depend on which tissue is of interest to the researcher.
Subcutaneous injection is the primary method for rodents according to published research - it is safer, it is easier to replicate and it achieves constant plasma levels. It has been used in some muscle healing studies by means of the intramuscular injection. The logic behind "injecting close to the damage" is based on the theory of depot injection: as the peptide is rapidly getting out of the blood but remains in the injured tissue's concentration, the injection close to the site of action may be more effective than subcutaneous injection. Although the above makes sense from the point of view of the mechanism of action, this hypothesis has never been investigated in a controlled experiment.
In comparison to other peptides, BPC-157 is rather special due to its stability in the gastric acid, as explained in the same study that confirmed its capacity to protect the gut from poisons. Stability is what allows for oral administration of BPC-157 unlike other peptides that get denaturalized in the process. The arginate salt form of the peptide is known to be used in oral capsules due to its assumed ability to improve absorption through the mucosa compared to other forms such as the acetate ones. As for the nasal dosage form, not much research on its effectiveness was carried out.
Reports on oral doses are typically higher than dosages that can be administered via injections, primarily due to the fact that injections can have unpredictable effects on the system. In spite of this, oral methods may also provide superior results compared to injectable methods for factors dealing with the gut, as in these cases, the peptide is applied in the area of the mucosa that needs the treatment. In terms of musculoskeletal concerns, however, it appears that injectable routes are superior based on the data available.
| Form | Bioavailability | Typical Research Dose | Best-Studied Use |
|---|---|---|---|
| Subcutaneous Injection | High (direct systemic). | 10 mcg/kg/day. | Tendon, ligament, muscle repair. |
| Intramuscular Injection | High (direct systemic). | 10 mcg/kg/day. | Muscle injury models. |
| Oral (acetate/arginate) | Lower, variable; stable in gastric acid. | 10-100 mcg/kg/day (model-dependent). | Gut mucosa, IBD models. |
| Nasal Spray | Unknown - no published data. | Not established. | No dedicated research. |
In animals, the safety data is quite remarkable for any substance that has such biological effects but with no great human study data available, there is little evidence to inform out decisions.
In studies involving rodents with doses far higher than usual research dosages, there has been no organ toxicity, significant weight change or behavioral effects attributable to the use of BPC-157. The only side effects extensively documented in animal studies concern injection-site reactions such as redness and minor swelling. There have been anecdotal accounts of nausea with human use, which could relate to the action of the peptide on gastric motility. Other than the Phase II IBD study focusing on a rectal application that cannot be compared with the systemic application, there is no safety data available from human studies.
The literature on rodent studies does not suggest any sex-based safety signals. The data from the studies mentioned above indicates no female-specific adverse effects are observed. The concern that arose in this context was about hormonal disturbance, but the available data concerning this mechanism does not support it – BPC-157 does not appear to interact with androgen or estrogen receptors.
It is the most crucial issue regarding safety, and therefore deserves an unequivocal answer. The mechanism through which BPC-157 stimulates angiogenesis is NO-VEGF. It is important to know that angiogenesis is crucial in the growth of tumors because, without recruiting blood vessels, the tumor will not grow beyond several millimeters. The issue is that the theoretical concern is that the BPC-157 potential property to stimulate existing undiagnosed tumors.
There has been no research involving rodents that indicates that BPC-157 is carcinogenic or capable of initiating tumor formation. Studies conducted on animals suffering from cancer have been conducted, and no signs of accelerated tumor growth have been found, although these studies were not meant to show whether the substance is carcinogenic. The FDA placed BPC-157 in Category 2 of the compounding list because of some safety concerns, based on more evidence than just cancer risk. Bottom line: there is no clear evidence supporting the notion that the substance causes cancer, though there may be concerns regarding its angiogenetic properties.
Kidney toxicity has been discussed in online forums, but the animal studies do not confirm it - renal histology in studies with rodents does not indicate that BPC-157 caused any pathologies. Regarding storage - yes, BPC-157 has to be stored in the fridge - the lyophilized powder has to be either in the fridge or in the freezer and away from light. After thawing and mixing with the bacteriostatic water, BPC-157 has to be stored at 2-8°C and used within about 4 weeks. The storage of the reconstituted peptide at room temperature leads to the faster breakdown of the compound and lower effective concentration, which is one of the most frequent mistakes made by scientists contacting us about their results.
BPC-157 has not received FDA approval as a medicine for any medical condition. In September 2023, the FDA categorized BPC-157 as a substance that poses significant safety concerns when used in compounding. It is classified as a category 2 substance, which means that compounding pharmacies operating under 503A regulations cannot use it as a bulk ingredient in compounding. However, it is not classified as a controlled substance under the Controlled Substances Act and is not prohibited for use or sale for valid scientific research purposes as of October 2023.
Indeed, BPC-157 is included in the WADA Prohibited List under S0 - Non-Approved Substances list as it lists any drug that has not been approved for use in humankind by any authority. The S0 rule is effective at any time both during and outside of competitions. Because NCAA follows the WADA prohibited list, BPC-157 is banned under NCAA regulations as well. Therefore, any athlete who undergoes anti-doping tests must consider BPC-157 a banned substance regardless of its name or form.
The compounding pharmacies used to make the BPC-157 drug prior to September 2023 using the 503A bulk drug framework - this means that these pharmacies can make compounds from bulk drugs that the FDA has not approved, but only if they follow certain rules. But after the introduction of its Category 2 status, this is no longer the case. Specifically, FDA's Category 2 classification identifies BPC-157 as significant safety issues, which is what allows for the compound to be removed from the eligibility list under 503A. Therefore, compounding pharmacies cannot create prescriptions for BPC-157 anymore according to the 503A framework. The research-supply market - containing vials meant specifically for labs - has become the only legitimate way to acquire the compound in the country.
Do note that major urine drug tests (like the 5-panel and 10-panel urine drug tests performed by virtually all employers today) do not typically screen for peptides. It is unlikely that one would find BPC-157 in the results of any such urine drug test. On the other hand, anti-doping testing done by sports organizations recognized by WADA is another story. The WADA recognized labs can test for a large variety of substances that have not been cleared for use and in accordance with its ban on the use of BPC-157, there is a strong possibility that it would be detected, but considering the quick nature of its half-life, the chances drop quickly.
When it is specified as “third-party tested”, it means that the producer has provided samples of the product for testing in a laboratory which is independent and has no business connection with the manufacturer. It should not be understood in the sense that the laboratory has given endorsement of the product for human consumption; this means that the data that can be found in the certificate of analysis has been obtained by other people different from the company that produced this order. The is tested by an independent laboratory AxisPharm, and as it has six samples, the number of the sample can be found on the container of the product. The purity of this product is 99.4%, and the following link provides full information on the subject matter.
Over the last 24 months, we reviewed certificates of analysis (COAs) from various suppliers. The material review is interesting: using high-performance liquid chromatography (HPLC), we found products ranging in purity from 94% to 99.6% from different suppliers and at least two lots from other suppliers without the mass spectrometry (MS) identity validation. A COA without identity validation provides little information.
A comprehensive certificate of analysis for a research peptide must contain the following: HPLC purity, which is the percentage of the peak area assigned to BPC-157; identification via mass spectrometry, which requires matching the measured molecular weight to the expected MW of BPC-157 (1419.5 Da); lot number; analysis date; and name of the testing laboratory. If any of these details are absent, the certificate is incomplete. The COA reading guide in this website provides detailed descriptions of each field along with relevant examples.
The BPC-157's market value in the US research supply industry is said to range between 45 for the 5mg vials to ¥55-$90 for the 10mg vials from reputable suppliers that have COAs to back them. Those selling at $25 or lower for their 5mg vials should see they perform quality checks on the purity documentation. The 10mg vial offered by US Peptide Labs goes for $65.00 for a single unit price or $61.75 each for orders of 2 units and above or $58.50 each for orders of 5 units and above, including free US shipping for orders of $70 and upwards. Such pricing puts US Peptide Labs in the mid-price range considering they are dealing with a 99.4% HPLC-verified product with Axispam COAs for every batch sold.
KPV, abbreviated as Lys-Pro-Val, is a tripeptide component of alpha-MSH. Its function is mainly tied to anti-inflammation in the epithelial layer of the intestines. The mechanism of action of BPC-157 involves the mechanism of NO-system and the mechanism of growth factors, while the mechanism of action of KPV entails the inhibition of NF-kB and modulation of the melanocortin receptor. KPV shows specifically anti-inflammatory properties, while BPC-157 has more general cytoprotective and wound healing properties. The combination is justified from the point of view of research.
These different types of peptides have different mechanisms of action and therefore different applications in research. Sermorelin is a GHRH analog because it stimulates secretion of GH by the pituitary gland. BPC-157 has not been shown to have any effect on GH-IGF-1 axis. The reason for the confusion is that their studies are usually framed inappropriately, so researchers do not know what to ask. If the objective of the research is to achieve GH secretion, then sermorelin should be chosen because it can be considered effective. However, if the objective of the study is to achieve tissue repair or gut protection, then it is BPC-157.
CJC-1295 is a type of GHRH analog known for its long-term performance in inducing higher levels of GH and IGF-1. It works exactly like sermorelin in that it uses the GH axis, which is not the pathway used by BPC-157 that operates via the FAK-paxillin system and the NO system. Thus, many experimental procedures use these two substances simultaneously. Their goals are complementary in that CJC-1295 achieves anabolic and metabolic results, whereas BPC-157 affects the processes in connective tissues and in the gastrointestinal tract. Mechanically, the substances do not work together, still, the experiments can be conducted together using the same experimental model.
| Peptide | Primary Research Area | Route | Typical Research Dose | Cycle |
|---|---|---|---|---|
| BPC-157 | Tendon, gut, angiogenesis. | SC, IM, oral. | 10 mcg/kg/day. | 4-8 weeks. |
| KPV | Gut inflammation (NF-kB). | Oral, SC. | 100-400 mcg/day (model-dependent). | 4-6 weeks. |
| Sermorelin | GH secretion, body composition. | SC. | 200-500 mcg/day. | 8-12 weeks. |
| CJC-1295 | Sustained GH/IGF-1 elevation. | SC. | 1-2 mg/week. | 8-12 weeks. |
Research has studied BPC-157 to establish its relationship with tendon and ligament healing, gut mucosal protection, angiogenesis, and NSAID-related damages. The compound has yet to receive any FDA-approved therapeutic use. Almost all available data comes from animal and in vitro studies, with only three pilot human studies cited in the latest literature review.
BPC-157 is distributed for laboratory research purposes only and has not been approved for therapeutic purposes for humans. In studies conducted on animals, 10 mcg/kg per day is established as the standard dose, which is usually given in one or two injections. The dosage table above indicates the standard dose based on different body weights in order to help researchers calculate the dose.
In terms of gut-specific endpoints, the use of oral BPC-157 has robust backing, as this peptide is able to maintain its stability under the acidic conditions of the stomach, enabling it to act locally in the mucosal area of the digestive tract. Due to the greater consistency of levels in the systemic circulation, injectable methods have greater support for musculoskeletal applications, particularly in the areas of ligaments, joints, and muscles. For oral capsules, arginate salts are the most suited form since they may lead to better absorption in the mucosa.
The BPC-157 is not classified as a controlled drug, which means that possession of this substance is not illegal in the US. The compound has not received FDA authorization and the 503A pharmacies are also not allowed to make it. Therefore the BPC-157 is legally sold as a substance to be used only in research labs. Therefore, the use of this compound to treat conditions does not conform to the necessary laws.
The answer to your question is that there are presently no approved uses of BPC-157 by the FDA. BPC-157 was tested in Phase II studies of IBD under the name PL 14736 using topical rectal formulation, but its NDA was never approved. The FDA classifies BPC-157 as a Category 2 substance due to its lack of approvals along with certain identified safety concerns.
There has not yet been seen in any rodent studies that BPC-157 begins tumor formation or acts as a carcinogenic agent. The hypothetical worry is that the pro-angiogenic action of BPC-157 may facilitate the vascularization of any pre-existing and non-diagnosed tumor. Numerous animal studies have utilized BPC-157 for cancer-positive models, but the use of the peptide has not led to any hastening of tumor development. The question cannot be answered with 100% certainty, since there is no human safety testing yet.
Plasma half-life is generally short, typically lasting for several minutes to several hours based on the route of administration as well as the model chosen. Unlike long-acting compounds, daily administration of BPC-157 does not lead to accumulation of the substance in blood plasma. Thus, no standard workplace drug testing is expected to reveal the presence of BPC-157. Detection of BPC-157 by doping control is a different matter depending on capabilities of WADA accredited laboratories and whether the compound is prohibited or not.
Yes. The NCAA operates according to the framework established by WADA and BPC-157 is included in the S0 category of the WADA prohibited list. Thus, it is banned at all times from usage for all athletes benefiting from the NCAA anti-doping rules.
The key requirements consist of HPLC purity in percentage terms rather than just making a bold statement such as “high purity”, mass spectrometry identity confirmation, and the recommendation for a specific independent testing laboratory and the appropriate lot number. The US Peptide Labs BPC-157 10 mg vial is compliant with all these requirements as it shows the results of 99.4% HPLC purity, AxisPharm CoA and six lots have been documented in the archives, the lot number printed at the bottom of the vial, and the price of $65.00 with free shipping from $70. And for research on healing and recovery protocols, the BPC-157 / TB-500 blend is also offered for combined musculoskeletal application at the cost of $85.00.
The items displayed on this web page are solely for laboratory research use, for individuals aged 21 years and above to carry out their research. The information contained in this report should not be construed as advice regarding health matters or directive for individual use. For full profile of the compounds, dosage and protocol references, log on to the BPC-157 peptide library page at Get US Peptides.